Glycyrrhizin Conjugated Dendrimer and Multi-Walled Carbon Nanotubes for Liver Specific Delivery of Doxorubicin.
The purpose of the present investigation was to investigate the drug targeting potential of glycyrrhizin (GL) conjugated dendrimers (GL-PPI) and multi walled carbon nanotubes (GL-MWCNTs) towards liver targeting of a model anti-cancer agent, doxorubicin (DOX). The synthesis was confirmed by FTIR, 1H-NMR and morphology analysis. Higher DOX loading was observed in case of GL-PPI-DOX and GL-MWCNT-DOX (43.02 ± 0.64% and 87.26 0.57%, respectively) than parent nanocarriers. GL attachment considerably reduced the haemolytic toxicity of DOX by 12.38 ± 1.05 and 7.30 ± 0.63% by GL-PPI-DOX and GL-MWCNT-DOX, respectively. MTT cytotoxicity studies, flow cytometry and cell morphology assessment was done in HepG2 cell. The IC50 of DOX was reduced from 4.19±0.05 µM to 2.0±0.01 and 2.7±0.03 µM, respectively by GL-PPI-DOX and GL-MWCNT-DOX, respectively. Flow cytometry and phase contrast microscopy confirmed GL conjugated formulations to be significantly dragging higher cancer cell number of cells in early apoptosis as well as in early apoptotic phase.
Prashant K
PK
Chopdey
Rakesh K
RK
Tekade
Neelesh K
NK
Mehra
Nishi
N
Mody
Narendra K
NK
Jain
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry; D050091:Dendrimers / Q000737:chemistry; D004058:Diffusion; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry; D004339:Drug Compounding / Q000379:methods; D019695:Glycyrrhizic Acid / Q000737:chemistry / Q000493:pharmacokinetics*; D056945:Hep G2 Cells; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry* / Q000648:ultrastructure; D058726:Nanoconjugates / Q000008:administration & dosage / Q000737:chemistry / Q000648:ultrastructure; D037742:Nanotubes, Carbon / Q000737:chemistry* / Q000648:ultrastructure; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D050091:Dendrimers; D053769:Nanocapsules; D058726:Nanoconjugates; D037742:Nanotubes, Carbon; D019695:Glycyrrhizic Acid; D004317:Doxorubicin